Relative risks for the various eye conditions in the RCGP study and the Oxford-FPA study according to oral contraceptive use. Never users of oral contraceptives have been taken as the reference category. Adjusted for age (5 year age groups)
| Oral contraceptives | |||||
|---|---|---|---|---|---|
| Condition | Study | No cases | Ever used | Recently used | Used in past |
| Conjunctivitis | RCGP | 5646 | 1.1 (1.0–1.1) | 1.2 (1.1–1.3) | 1.0 (1.0–1.1) |
| Ox-FPA | 183 | 1.3 (0.9–1.9) | 1.7 (1.3–2.2) | 1.1 (0.7–1.7) | |
| Keratitis | RCGP | 199 | 0.8 (0.6–1.1) | 0.9 (0.6–1.4) | 0.8 (0.6–1.1) |
| Ox-FPA | 54 | 1.0 (0.5–1.7) | 1.4 (0.7–2.6) | 0.7 (0.3–1.4) | |
| Iritis | RCGP | 187 | 0.8 (0.6–1.0) | 0.7 (0.5–1.0) | 0.6 (0.5–0.9) |
| Ox-FPA | 51 | 1.1 (0.6–2.0) | 1.1 (0.5–2.4) | 1.1 (0.6–2.1) | |
| Lacrimal disease | RCGP | 246 | 1.2 (1.0–1.6) | 1.4 (1.0–1.9) | 1.0 (0.8–1.4) |
| Ox-FPA | 63 | 0.8 (0.5–1.4) | 0.8 (0.3–1.6) | 0.9 (0.5–1.5) | |
| Strabismus | RCGP | 59 | 0.9 (0.6–1.6) | 0.6 (0.3–1.3) | 1.0 (0.6–1.7) |
| Ox-FPA | 33 | 0.6 (0.3–1.3) | 0.7 (0.3–1.7) | 0.5 (0.2–1.2) | |
| Cataract | RCGP | 170 | 0.8 (0.6–1.0) | 0.3 (0.2–0.6) | 0.8 (0.6–1.1) |
| Ox-FPA | 48 | 1.6 (0.8–2.9) | 3.7 (1.6–8.2) | 1.1 (0.6–2.3) | |
| Glaucoma | RCGP | 127 | 1.0 (0.7–1.4) | 0.8 (0.4–1.9) | 1.0 (0.7–1.5) |
| Ox-FPA | 58 | 1.6 (0.9–2.0) | 1.2 (0.3–3.5) | 1.7 (1.0–3.0) | |
| Retinal detachment | RCGP | 38 | 0.8 (0.4–1.4) | 0.6 (0.3–1.4) | 0.6 (0.3–1.3) |
| Ox-FPA | 30 | 2.3 (1.0–5.7) | 2.1 (0.6–7.0) | 2.4 (1.0–6.1) | |
| Retinal vascular lesions | RCGP | 71 | 1.3 (0.8–2.0) | 2.0 (1.0–3.8) | 1.0 (0.6–1.7) |
| Ox-FPA | 25 | 1.9 (0.8–4.7) | 2.4 (0.4–9.2) | 1.9 (0.7–4.6) | |
↵p<0.05.
Periods of observation (person years):
RCGP:
Never used 218 974
Ever used 319 652
Recently used 131 090
Used in past 188 562
Oxford-FPA:
Never used 123 082
Ever used 185 927
Recently used 73 713
Used in past 112 214.